IP Library Granted Patent US 11,685,899
Granted Patent B2
US 11,685,899 · App. 16/599,271 · Granted Jun 27, 2023

Cell culture method for mesenchymal stem cells

Inventors: Paul Simmons (Melbourne, AU); Colby Suire (New York, NY)
Assignee: MESOBLAST INTERNATIONAL SARL
C12N5/0662C12N2500/99C12N2501/11C12N2501/115C12N2501/135
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,685,899
App. No.
16/599,271
Granted
Jun 27, 2023
Kind
B2
Abstract

The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.

Claims (12)

1. An in vitro method of cell culture, the method comprising:

culturing a population of mesenchymal lineage precursor cells or stem cells in a fetal bovine serum free cell culture medium comprising platelet derived growth factor (PDGF), epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2), wherein the level of PDGF is 10 ng/ml or less, the level of EGF is 5 ng/mi or less, and the level of FGF2 is 1 ng/ml or less, wherein the method increases mesenchymal lineage precursor cell or stem cell proliferation.

2. The method of claim 1 , wherein the level of FGF2 is between 2 pg/ml and 1 ng/ml.

3. The method of claim 1 , wherein the level of FGF2 is 1 ng/ml.

4. The method of claim 1 , wherein the PDGF is PDGF-BB.

5. The method of claim 4 , wherein the level of PDGF-BB is 10 ng/ml.

6. The method of claim 1 , wherein the level of EGF is between 0.08 ng/ml and 5 ng/ml.

7. The method of claim 1 , wherein the level of EGF is between 3 ng/ml and 5 ng/ml.

8. The method of claim 1 , wherein the cell culture medium comprises alpha-minimal essential medium.

9. The method of claim 1 , wherein the cell culture medium maintains the mesenchymal lineage progenitor or stem cells in an undifferentiated state.

10. The method of claim 1 , wherein culturing the population of mesenchymal lineage precursor or stem cells promotes cell proliferation relative to a control population of mesenchymal lineage precursor or stem cells cultured in a fetal bovine serum free cell culture medium without PDGF or FGF2.

11. The method of claim 1 , wherein the mesenchymal lineage precursor cell or stem cell is a mesenchymal lineage precursor cell.

Assignments (3)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: SIMMONS, PAUL; SUIRE, COLBY
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 050719/0520 →